// App-Quantinova.ai

152 : Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014.

Researchers

Presenter

  • Thomas W. Flaig

Principal Investigators

  • Catherine M. Tangen

  • Hari Anant Deshpande

  • Ulka N. Vaishampayan

  • Ian Murchie Thompson

  • Maha Hussain

  • Neeraj AgarwAlNicholas Mitsiades

Medical Centers

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Fred Hutchinson Cancer Research Center, Seattle, WABaylor College of Medicine, Houston, TXHuntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Yale Cancer Center, New Haven, CT

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • University of Colorado Cancer Center, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved